Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women

British Journal of Clinical Pharmacology

Volumn 66, Issue 2, 2008, Pages 179-195

  Roustit, Matthieu ^b,c   Jlaiel, Malik ^c   Leclercq, Pascale ^c   Stanke Labesque, Françoise ^a,b,c,d  

^a HÔPITAL MICHALLON   (France)

^b University Grenoble Alpes   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d UNIV GRENOBLE ALPES   (France)

Author keywords

Antiretrovirals; HIV mother to child transmission; Pharmacokinetics; Pregnancy; Protease inhibitors; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CYTOCHROME P450; CYTOCHROME P450 3A; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; GLYCOPROTEIN P; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; OROSOMUCOID; PREGNANE X RECEPTOR; PROGESTERONE; PROTEINASE INHIBITOR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SERUM ALBUMIN; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; FEMALE; GLUCOSE INTOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INSULIN RESISTANCE; LIVER TOXICITY; LOW DRUG DOSE; PREGNANT WOMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; VERTICAL TRANSMISSION;

EID: 47249138651     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03220.x     Document Type: Review

References (142)

1. UNAIDS. Report on the Global AIDS Epidemic. Geneva : WHO, 2006. Available at http://www.unaids.org (last accessed 23 July 2007).
2. Girard P, Katlama C, Pialoux G. VIH, Pairs: Doln, 2004.
3. EPF. Evolution des inclusions et du recrutement dans EPF ANRS CO1-CO11, 2006. Available at u569.kb.inserm.fr (last accessed 23 July 2007).
4. Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004. Pediatrics 2007 119 : e900 6.
5. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, Faye A, Burgard M, Rouzioux C, Mandelbrot L. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008 22 : 289 99.
6. World Health Organization, Inter-Agency Task Team on Prevention of HIV infection in Pregnant Women, Mothers and their Children. Guidance on global scale-up of the prevention of mother to child transmission of HIV: towards universal access for women, infants and young children and eliminating HIV and AIDS among children. 2007. Available at http://www.who.int/hiv/mtct/ PMTCT_enWEBNov26.pdf (last accessed: 19 February 2008).
7. Mock PA, Shaffer N, Bhadrakom C, Siriwasin W, Chotpitayasunondh T, Chearskul S, Young NL, Roongpisuthipong A, Chinayon P, Kalish ML, Parekh B, Mastro TD. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS 1999 13 : 407 14.
8. Leroy V, Montcho C, Manigart O, Van de Perre P, Dabis F, Msellati P, Meda N, You B, Simonon A, Rouzioux C. Maternal plasma viral load, zidovudine and mother-to-child transmission of HIV-1 in Africa: DITRAME ANRS 049a trial. AIDS 2001 15 : 517 22.
9. Jamieson DJ, Sibailly TS, Sadek R, Roels TH, Ekpini ER, Boni-Ouattara E, Karon JM, Nkengasong J, Greenberg AE, Wiktor SZ. HIV-1 viral load and other risk factors for mother-to-child transmission of HIV-1 in a breast-feeding population in Cote d'Ivoire. J Acquir Immune Defic Syndr 2003 34 : 430 6.
10. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, Mwatha A, Overbaugh J, Bwayo J, Ndinya-Achola JO, Kreiss JK. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001 183 : 206 12.
11. WHO. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Geneva : WHO, 2004. Available at http://www.who.int (last accessed 23 July 2007).
12. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006 296 : 827 43.
13. Yeni P. Prise en charge médicale des personnes infectées par le VIH: recommandations du groupe d'experts. Paris : Fammarion Médecine-Sciences, 2006.
14. Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, Peytavin G, Regazzi M, Back D. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther 2005 10 : 375 92.
15. Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004 43 : 845 53.
16. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 2000 30 (Suppl. 2 S151 9.
17. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2006. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf (last accessed: 25 April 2007).
18. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997 33 : 328 43.
19. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005 44 : 989 1008.
20. Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001 15 : 819 26.
21. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004 43 : 1071 87.
22. Rakhmanina NY, van den Anker JN, Soldin SJ. Safety and pharmacokinetics of antiretroviral therapy during pregnancy. Ther Drug Monit 2004 26 : 110 5.
23. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, Goodwin C, Harrigan PR, Moore KH, Stone C, Plumb R, Johnson MA. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998 178 : 1327 33.
24. Watts DH, Brown ZA, Tartaglione T, Burchett SK, Opheim K, Coombs R, Corey L. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991 163 : 226 32.
25. Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, Read JS, Smith E, Hu C, Spector SA, Connor JD. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006 20 : 553 60.
26. Burchett S, Best B, Mirochnick M, Hu C, Capparelli E, Holland D, Smith E, Sheeran B, Read J, Stek A. Tenofovir Pharmacokinetics during Pregnancy, at Delivery and Postpartum. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
27. Hirt D, Urien S, Rey E, Arrive E, Avit D, Gray V, Nerrienet E, Ekouevi D, Dabis F, Treluyer JM. Population Pharmacokinetics of Emtricitabine in HIV-infected Pregnant Women and Their Neonates: Temaa ANRS 12109. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008.
28. Best B, Stek A, Hu C, Burchett SK, Rossi S, Smith E, Sheeran B, Read J, Capparelli E, Mirochnick M. High-dose Lopinavir and Standard-dose Emtricitabine Pharmacokinetics during Pregnancy and Postpartum. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008.
29. Brennan-Benson P, Pakianathan M, Rice P, Bonora S, Chakraborty R, Sharland M, Hay P. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS 2006 20 : 297 9.
30. Ferreira C, Ceccaldi P, Visseaux B, Gavard L, Peytavin G, Gil S, Mandelbrot L. Lack of Placental Transfer of Enfuvirtide in an ex vivo Human Placental Cotyledon Perfusion Model. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
31. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001 40 : 893 905.
32. Sustiva® (Product labeling), Bristol-Myers Squibb Company, Princeton, NJ, USA. January 2007.
33. Jeantils V, Khuong MA, Delassus JL, Honoré P, Taverne B, Uzan M, Tassi S. Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients. Gynecol Obstet Fertil 2006 34 : 593 6.
34. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. October 12, 2006 1 65. Available at http://aidsinfo.nih.gov/ ContentFiles/PerinatalGL.pdf (last accessed 25 April 2007).
35. Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, Provisor A, Thorpe EM, Paul ME, Foca M, Gandia J, Huang S, Wei LJ, Stevens LM, Watts DH, McNamara J. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004 36 : 772 6.
36. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 2002 30 : 200 15.
37. Giaquinto C, Rampon O, De Rossi A. Antiretroviral therapy for prevention of mother-to-child HIV transmission: focus on single-dose nevirapine. Clin Drug Investig 2006 26 : 611 27.
38. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mazhani L, Novitsky V, Lagakos S, Essex M. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007 356 : 135 47.
39. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998 178 : 368 74.
40. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999 13 : 479 86.
41. Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001 20 : 803 5.
42. Aweeka F, Lizak P, Frenkel L, Au S, Watts H, McNamara J, Stevens L, Hitti J. Steady State Nevirapine Pharmacokinetics during Second and Third Trimester Pregnancy and Postpartum: PACTG 1022. In: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004.
43. von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S, Haberl A. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 2006 62 : 552 9.
44. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH, Hoetelmans RM. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001 15 : 1089 95.
45. de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, van der Ende ME. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003 42 : 599 605.
46. Gingelmaier A, Kurowski M, Kästner R, Eberle J, Mylonas I, Belohradsky BH, Friese K, Grubert TA. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006 20 : 1737 43.
47. Intelence® (Product labeling), Tibotec Inc. January 2008.
48. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, Irion O, Kaiser L. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998 12 : F241 7.
49. European Collaborative Study; Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000 14 : 2913 20.
50. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, O'Sullivan MJ, Scott G, Stek AM, Wara D, Bulterys M. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002 346 : 1863 70.
51. Szyld EG, Warley EM, Freimanis L, Gonin R, Cahn PE, Calvet GA, Duarte G, Melo VH, Read JS. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006 20 : 2345 53.
52. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006 193 : 1195 201.
53. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007 21 : 607 15.
54. Watts DH, Balasubramanian R, Maupin RT Jr., Delke I, Dorenbaum A, Fiore S, Newell ML, Delfraissy JF, Gelber RD, Mofenson LM, Culnane M, Cunningham CK. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004 190 : 506 16.
55. Tang JH, Sheffield JS, Grimes J, McElwee B, Roberts SW, Laibl V, McIntire DD, Wendel GD Jr. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006 107 : 1115 9.
56. Hitti J, Andersen J, McComsey G, Liu T, Melvin A, Smith L, Stek A, Aberg J, Hull A, Alston-Smith B, Watts DH, Livingston E. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007 196 : 331.e1 7.
57. Watts DH. Treating HIV during pregnancy: an update on safety issues. Drug Saf 2006 29 : 467 90.
58. Viracept® (Product labeling), Agouron Pharmaceuticals Inc. January 2001.
59. Perry CM, Frampton JE, McCormack PL, Siddiqui MA, Cvetkovic RS. Nelfinavir: a review of its use in the management of HIV infection. Drugs 2005 65 : 2209 44.
60. Bryson Y, Stek A, Mirochnick M, Connor J, Huang S, Hughes M, Mofenson L, Culane M, Snidow J, Gersten M. PACTG 353 A Phase I Study of Safety, Pharmacokinetics, and Antiviral Activity of Combination Nelfinavir (NFV), ZDV, and 3TC in HIV-Infected Pregnant Women and Their Infants. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2000.
61. Bryson Y, Stek A, Mirochnick M, Mofenson L, Connor J, Watts H, Huang S, Hughes M, Cunningham B, Asfaw Y, Smith E. Pharmacokinetics, Antiviral Activity, and Safety of Nelfinavir (NFV) with ZDV/3TC in Pregnant HIV-Infected Women and Their Infants: PACTG 353 Cohort 2. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002.
62. Angel JB, Khaliq Y, Monpetit ML, Cameron DW, Gallicano K. An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy. AIDS 2001 15 : 417 9.
63. Burger DM, Grintjes KJ, Lotgering FK, Koopmans PP. Therapeutic drug monitoring of nelfinavir in pregnancy: a case report. Ther Drug Monit 2004 26 : 576 8.
64. Villani P, Floridia M, Pirillo MF, Cusato M, Tamburrini E, Cavaliere AF, Guaraldi G, Vanzini C, Molinari A, degli Antoni A, Regazzi M. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol 2006 62 : 309 15.
65. van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004 76 : 588 97.
66. Khuong-Josses MA, Boussairi A, Herida M, Abbas S, Méchali D. Nelfinavir Plasma Concentrations in 40 Pregnant Women. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006.
67. Nellen JF, Schillevoort I, Wit FW, Bergshoeff AS, Godfried MH, Boer K, Lange JM, Burger DM, Prins JM. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis 2004 39 : 736 40.
68. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003 17 : 1195 9.
69. Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R, Lange J. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003 17 : 1157 65.
70. Aweeka F, Tierney C, Stek A, Sun X, Cohn S, Coombs R, Lizak P, Kmack A, Klingman K, Sha B. ACTG 5153s: Pharmacokinetic Exposure and Virological Response in HIV-1-infected Pregnant Women Treated with PI. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
71. Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother 2006 50 : 2079 86.
72. Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002 16 : 1331 40.
73. Read J, Best B, Stek A, Hu C, Capparelli E, Holland D, Burchett S, Smith E, Sheeran B, Mirochnick M. Nelfinavir Pharmacokinetics (625-mg Tablets) during the Third Trimester of Pregnancy and Post-partum. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
74. Kakehasi FM, Tupinanmbas U, Cleto S, Aleixo A, Lin E, Melo V, Aguiar R, Pinto J. High rate of nelfinavir-associated mutations observed among women exposed to prophylactic antiretroviral during pregnancy. XVI International AIDS Conference, Toronto, 2006.
75. Invirase® (Product labeling), Roche Pharmaceuticals Inc. October 2000.
76. Fortovase® (Product labeling), Roche Pharmaceuticals Inc. October 2000.
77. Acosta EP, Zorrilla C, Van Dyke R, Bardeguez A, Smith E, Hughes M, Huang S, Pitt J, Watts H, Mofenson L. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001 2 : 460 5.
78. Vithayasai V, Moyle GJ, Supajatura V, Wattanatchariya N, Kanshana S, Sirichthaporn P, Dabtham K, Somburanasin P, Chantawuttinan T, Hill AM, Hawkins D. Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission. J Acquir Immune Defic Syndr 2002 30 : 410 2.
79. Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, Pompeo L, Stek AM, Pitt J, Watts DH, Smith E, Jimenez E, Mofenson L. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004 48 : 430 6.
80. Hawkins DA, Khan W, Moyle GJ, Penn Z, Lyall H, Back D, Hill A. Pharmacokinetics (PK), safety, tolerability and efficacy of saquinavir hard-gel capsules/ritonavir (SQV/r) plus 2 nucleosides in HIV-1-infected pregnant women. XV International AIDS Conference, Bangkok, 2004.
81. Burger D, Eggink A, Van der Ende I, Hawkins D, Vogel M, Fatkenheuer G, Molto J, Richter C, Koopmans P, Schutz M The Pharmacokinetics of Saquinavir in New Tablet Formulation + Ritonavir (1000/100 mg Twice Daily) in HIV-1-infected Pregnant Women. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
82. Tung M, Boffito M, Taylor S, Short J, Gibbons S, Back D, Khan W, Hawkins D. Pharmacokinetics (PK), safety, tolerability and efficacy of boosted saquinavir 500 mg film coated tablets in a regimen of 1000/100 mg bid plus 2 nucleoside analogues (NRTIs) in HIV+ pregnant women. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, 2006.
83. Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, Garcia-Lazaro M, Viciana P, Rodriguez-Banos J, Ocampo A. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit 2007 29 : 171 6.
84. Zorrilla CD, Van Dyke R, Bardeguez A, Acosta EP, Smith B, Hughes MD, Huang S, Watts DH, Heckman B, Jimenez E, McSherry G, Mofenson L. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrob Agents Chemother 2007 51 : 2208 10.
85. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996 124 : 1039 50.
86. Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, Breitenbach J, Morris JB, Brun SC, Hanna GJ. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007 44 : 401 10.
87. Kaletra® (Product labeling), Abbott Laboratories, Abbott Park, Illinois, USA. September 15, 2000.
88. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS. Reduced lopinavir exposure during pregnancy. AIDS 2006 20 : 1931 39.
89. Mirochnick M, Stek A, Capparelli E, Best B, Holland D, Connor J, Burchett S, Hu C, Smith E, Read J. Adequate Lopinavir Exposure Achieved with a Higher Dose during the Third Trimester of Pregnancy. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006.
90. Lyons F, Lechelt M, De Ruiter A. Steady-state lopinavir levels in third trimester of pregnancy. AIDS 2007 21 : 1053 4.
91. Cassard B, Rouault A, Damond F, Pattyn A, Batallan A, Legac S, Peytavin G, Matheron S. Therapeutic Drug Monitoring of Lopinavir/ritonavir (LPV/r) Containing Regimen in Pregnant HIV-infected Women. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, 2005.
92. Caswell R, Doshi S, Khoo S, Chaponga M, Poulton M, Welch J, Gibbon S, McDonald C, Lambert J. Therapeutic drug monitoring (TDM): is it of clinical utility in HIV+ pregnant women? 8th International Congress on Drug Therapy in HIV Infection, Glasgow, 2006.
93. Khuong-Josses MA, Boussaïri A, Palette C, Méchali D. Lopinavir Drug Monitoring in 36 Pregnant Women. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
94. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS 2007 21 : 643 5.
95. Peytavin G, Pierre-François S, Cassard B, de Truchis P, Winter C, Visseaux B, Damond F, Tubiana R, Mandelbrot L, Matheron S. Reduced Lopinavir Exposure during Pregnancy: A Case Control Study. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
96. Sovric M, Gingelmaier A, Kaestner R, Weissenbacher T, Mylonas I, Friese K. Lopinavir/ritonavir during the pregnancy of HIV-infected women. XVI International AIDS Conference, Toronto, 2006.
97. Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Di Garbo A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 2002 16 : 2081 3.
98. Gonzalez de Requena D, Gallego O, Valer L, Jimenez-Nacher I, Soriano V. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 2004 20 : 275 8.
99. Bouillon-Pichault M, Jullien V, Azria E, Panier E, Firtion G, Krivine A, Compagnucci A, Taulera O, Launay O, Treluyer JM. Lopinavir Population Pharmacokinetics on HIV-infected Pregnant Women. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2008.
100. Khuong-Josses MA, Azerad D, Boussairi A, Ekoukou D. Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women. HIV Clin Trials 2007 8 : 254 5.
101. Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 1997 19 : 159 75.
102. Unadkat JD, Wara DW, Hughes MD, Mathias AA, Holland DT, Paul ME, Connor J, Huang S, Nguyen BY, Watts DH, Mofenson LM, Smith E, Deutsch P, Kaiser KA, Tuomala RE. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2007 51 : 783 6.
103. Hayashi S, Beckerman K, Homma M, Kosel BW, Aweeka FT. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS 2000 14 : 1061 2.
104. Tubiana R, Dominguez S, Perot C, Cornelie C, Marcelin A, Pauchard M, Ouagari Z, Ghosn J, Peytavin G, De Montgolfier I, Agher R, Calvez V, Bricaire F, Dommergues M, Katlama C. ART with Indinavir with Ritonavir (400 mg/100 mg Twice Daily)-containing Regimen in HIV-1-infected Pregnant Women. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2005.
105. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005 44 : 1035 50.
106. Lechelt M, Lyons F, Clarke A, Magaya V, Issa R, de Ruiter A. Human placental transfer of atazanavir: a case report. AIDS 2006 20 : 307.
107. Morris A, Juethner S, Theroux E. Atazanavir use in pregnancy. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, 2005.
108. Natha M, Hay P, Taylor G, Brook G, Sarner L, Cunningham L, Watson J, Wood C, Anderson J, de Ruiter A, Group PP. Atazanavir Use in Pregnancy: A Report of 33 Cases. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
109. Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007 21 : 2409 15.
110. Eley T, Vandeloise E, Child M, Conradie F, Zorrilla C, Josipovic D, Wang Y, Yang R, McGrath D, Bertz RJ. Steady State Pharmacokinetics and Safety of Atazanavir after Treatment with ATV 300 mg Once Daily/Ritonavir 100 mg Once Daily + ZDV/3TC during the Third Trimester in HIV+ Women. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2008.
111. Fulco PP, Vora UB, Bearman GM. Acid suppressive therapy and the effects on protease inhibitors. Ann Pharmacother 2006 40 : 1974 83.
112. Scott G, Rodman J, Scott W, Shapiro D, Huang S, Smith E, Mofenson L, Watts H, O'Sullivan M. Pharmacokinetic and Virologic Response to Ritonavir (RTV) in Combination with Zidovudine (ZDV) and Lamivudine (3TC) in HIV-1 Infected Pregnant Women and Their Infants. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002.
113. Mirochnick M, Bryson Y, Stek A, Mofenson L, Connor J, Watts H, Huang S, Hughes M, Cunningham-Schrader B, Purdue L, Asfaw Y, Smith E. Pharmacokinetics (PK) of Nelfinavir (NFV) and Its M8 Metabolite in Pregnant HIV-Infected Women and Their Infants: PACTG 353. Pediatric Academic Societies Meeting, Seattle, WA, 2003.
114. McGready R, Stepniewska K, Seaton E, Cho T, Cho D, Ginsberg A, Edstein MD, Ashley E, Looareesuwan S, White NJ, Nosten F. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 2003 59 : 553 7.
115. Tracy TS, Venkataramanan R, Glover DD, Caritis SN. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 2005 192 : 633 9.
116. Mathias AA, Maggio-Price L, Lai Y, Gupta A, Unadkat JD. Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther 2006 316 : 1202 9.
117. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003 42 : 1331 57.
118. Back DJ, Khoo SH. The role of clinical pharmacology in optimizing antiretroviral therapy. Br J Clin Pharmacol 2003 55 : 473 6.
119. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007 73 : 1573 81.
120. Molsa M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C, Laine K. Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther 2005 78 : 123 31.
121. Gil S, Saura R, Forestier F, Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta 2005 26 : 268 70.
122. Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 2007 377 : 1 13.
123. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003 19 : 825 35.
124. Chu CY, Singla VP, Wang HP, Sweet B, Lai LT. Plasma alpha 1-acid glycoprotein levels in pregnancy. Clin Chim Acta 1981 112 : 235 40.
125. Aweeka F, Stek A, Best B, Hu C, Holland D, Hermes A, Burchett S, Read J, Mirochnick M, Capparelli E. Lopinavir Protein Binding during Pregnancy. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
126. Boffito M, Hoggard PG, Reynolds HE, Bonora S, Meaden ER, Sinicco A, Di Perri G, Back DJ. The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. Br J Clin Pharmacol 2002 54 : 262 8.
127. Else L, Dickinson C, Bell C, Douglas M, Back D, Khoo SH, Taylor G. Total and unbound lopinavir (LPV) pharmacokinetics (PK) during pregnancy and at delivery in HIV-infected women. 8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, 2007.
128. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet 2007 46 : 209 19.
129. Pacheco LD, Ghulmiyyah LM, Snodgrass WR, Hankins GD. Pharmacokinetics of corticosteroids during pregnancy. Am J Perinatol 2007 24 : 79 82.
130. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003 73 : 330 7.
131. van der Leur MR, Burger DM, la Porte CJ, Koopmans PP. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit 2006 28 : 650 3.
132. Watts DH, Lambert J, Stiehm ER, Harris DR, Bethel J, Mofenson L, Meyer WA III., Mathieson B, Fowler MG, Nemo G. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 2003 33 : 585 93.
133. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005 19 : 63 7.
134. Overton ET, Sungkanuparph S, Nurutdinova D, Powderly WG. Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy. AIDS 2005 19 : 1439.
135. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007 36 : 1009 21.
136. Duran AS, Losso MH, Saloman H, Harris DR, Pampuro S, Soto-Ramirez LE, Duarte G, de Souza RS, Read JS. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis. AIDS 2007 21 : 199 205.
137. Watts DH, Mofenson L, Lu M, Thompson B. Treatment Interruption after Pregnancy and Disease Progression: A Report from the Women and Infants Transmission Study. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
138. van Schalkwyk J, Chaworth-Musters T, Maan E, Gilgoff S, Tatum S, Burdge D, Forbes J, Alimenti A, Money D. Time to HIV Suppression with HAART in Pregnancy. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
139. Bardeguez A, Lindsey J, Shannon M, Cohn S, Read J, Smith E, Tuomala R. Adherence to ART in US Women during and after Pregnancy. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006.
140. Vaz MJ, Barros SM, Palacios R, Senise JF, Lunardi L, Amed AM, Castelo A. HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women. Int J STD AIDS 2007 18 : 28 32.
141. Ciraru-Vigneron N, Lefevre V, Mazeron MC, Burgard M, Bergmann JF. Compliance to ART in Pregnant Women. Incidence on Mother-to-Child Transmission. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2005.
142. Molto J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, Delavarga M, Fumaz CR, Barbanoj MJ, Clotet B. Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol 2007 63 : 715 21.